Clinical Trial Update: ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for ONC201 in recurrent/refractory metastatic breast cancer and advanced endometrial carcinoma has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• ONC201 (ONC201)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Triple Negative Breast Cancer, Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-01-12